Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020
US$ 3,500.00
Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020 SUMMARY Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involve...
January 2020
192 pages
Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020
US$ 3,500.00
Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020'; Tyrosine Protein Kinase JAK3 (Ja...
January 2020
138 pages
Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020
US$ 3,500.00
Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020 SUMMARY Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is a...
January 2020
122 pages
Hemophilia A - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
212 pages
Bladder Cancer - Pipeline Review, H2 2019
US$ 2,500.00
... releases. The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
1626 pages
Age Related Macular Degeneration - Pipeline Review, H2 2019
US$ 2,500.00
... releases. The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
753 pages
Wounds - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
224 pages
Macular Edema - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
87 pages
Retinal Vein Occlusion - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
107 pages
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2019
US$ 2,000.00
... . The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
70 pages
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
234 pages
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
561 pages
Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2019
US$ 2,500.00
... releases. The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
2467 pages
Medulloblastoma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
346 pages
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
1370 pages
Neuroendocrine Tumors - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
692 pages
Recurrent Malignant Glioma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
62 pages
Hyperglycemia - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
31 pages
Keloids - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
55 pages
Small-Cell Lung Cancer - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
1225 pages
Activin Receptor Type 1 - Pipeline Review, H2 2019
US$ 3,500.00
... releases. The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
75 pages
High-Grade Glioma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
568 pages
Western Equine Encephalitis - Pipeline Review, H2 2019
US$ 2,000.00
... . The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
33 pages
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Mucopolysaccharidosis I (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
106 pages
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2019
US$ 2,000.00
... Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under ...
December 2019
58 pages
Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
173 pages
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019
US$ 3,500.00
... Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
84 pages
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019
US$ 3,500.00
... Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
156 pages
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019
US$ 3,500.00
... Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
88 pages
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2019
US$ 2,000.00
... . The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
127 pages
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2019
US$ 3,500.00
... Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
34 pages
Dystrophin (DMD) - Pipeline Review, H2 2019
US$ 3,500.00
... reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
117 pages
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019
US$ 3,500.00
... Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
51 pages
Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019
US$ 3,500.00
... Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
76 pages
Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019
US$ 3,500.00
... Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
81 pages
Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape Develop and design in-licensing and ...
December 2019
34 pages
Radiodermatitis - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
49 pages
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape Develop and design in-licensing and ...
December 2019
67 pages
Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape Develop and design in-licensing and ...
December 2019
78 pages
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
118 pages
Meningioma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
349 pages
Hemochromatosis - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
45 pages
Vulvar Cancer - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
243 pages
Familial Amyloid Neuropathies - Pipeline Review, H2 2019
US$ 2,000.00
... . The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
102 pages
Graves' Ophthalmopathy - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
77 pages
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
303 pages
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
66 pages
